How do you approach the discussion regarding loss of muscle mass with GLP-1 agonists in your non-geriatric population where the negative repercussions may not be as obvious?

We start by having the discussion PRIOR to starting the medication. We educate that this is not a GLP-1 phenomenon but a result of weight loss. We reinforce this at every dose change and at every follow-up, emphasizing protein and strength training. We use a body composition analysis scale to help p...

I mention this along with the other negative risks of GLP-1s. I consider this part of informed consent. So topics usually discussed are

1. Main side effects such as nausea/vomiting/GI upset, etc.
2. That these medications are likely to be considered chronic medications, as recent analysis shows 60% of we...